DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ztcf6r/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Arsanis Biosciences GmbH
- Cellceutix Corporation
- Debiopharm International S.A.
- Melinta Therapeutics, Inc
- Merck & Co., Inc.
- Northern Antibiotics Oy
- Nosopharm SAS
- Novan, Inc.
- Pfizer Inc.
- Phico Therapeutics Ltd.
- Sarepta Therapeutics, Inc.
- Shionogi & Co., Ltd.
- Soligenix, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Syntiron LLC
- Tetraphase Pharmaceuticals Inc.
- Theraclone Sciences, Inc.
- Trana Discovery, Inc.
Drug Profiles
- Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections
- Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections
- BXN-112
- CB-027
- CB-618
- CC-1807
- CTIX-1278
- Debio-1454
- dusquetide
- IBN-1
- Klebsiella pneumoniae vaccine
- Monoclonal Antibodies for Klebsiella Pneumoniae Infections
- Monoclonal Antibody for Klebsiella Pneumoniae Infections
- MVX-506
- NAB-7061
- NAB-739
- NAB-741
- NOSO-95300
- NVN-1000
- NVN-4428
- PT-4
- RX-05
- RXP-792
- RXP-873
- S-649266
- Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections
- SM-295291
- SM-369926
- Small Molecule for Gram-Negative Nosocomial Infections
- Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections
- Small Molecules to Inhibit DHFR for Infectious Diseases
- TP-076
- TP-138
- TP-600
For more information visit http://www.researchandmarkets.com/research/ztcf6r/klebsiella
